Ilorasertib hydrochloride

CAS No.	1847485-91-9	Cat. No.	BCP45536
Name	Ilorasertib hydrochloride
Synonyms	ABT348; ABT-348; ABT 348; Abbott 968660; Abbott-968660;ABT-348 hydrochloride;
Formula	C25H22ClFN6O2S	M. Wt	525.0

Description	Ilorasertib, also know as ABT-348, is a novel, potent and orally bioavailable inhibitor of the Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases and is currently in Phase I clinical trials. ABT-348 has nanomolar potency (IC50) for inhibiting binding and cellular auto-phosphorylation of Aurora B (7 and 13 nM), C (1 and 13 nM) and A (120 and 189 nM). Based upon its unique spectrum of activity, ABT 348 was evaluated and found effective in representative solid tumor (HT1080 and MiaPaCa, tumor stasis) and hematological malignancy (RS4;11, regression) xenografts. These results provide the rationale for clinical assessment of ABT-348 as a therapeutic agent in the treatment of cancer.
Related Products	1227939-82-3（Ilorasertib）
Pathways	Cell Cycle/DNA Damage
Targets	Aurora

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.